Biomarkers of response to PD-1/PD-L1 inhibition
- PMID: 28693793
- DOI: 10.1016/j.critrevonc.2017.06.001
Biomarkers of response to PD-1/PD-L1 inhibition
Abstract
Immunotherapy is a promising treatment strategy for cancer that has recently shown unprecedented survival benefits in selected patients. A number of immunomodulatory agents that target immune system checkpoints such as the cytotoxic T-lymphocyte antigen 4 (CTLA-4), the programmed death-1 (PD-1) or its ligand (PD-L1), have received regulatory approval for the treatment of multiple cancers including malignant melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, and recurrent or metastatic head and neck squamous cell carcinoma. Nevertheless, a substantial proportion of patients treated with checkpoint inhibitors have little or no benefit while these treatments are costly and might have associated toxicities. Hence, the establishment of valid predictors of treatment response has become a priority. This review summarizes the current evidence around biomarkers of response to PD-1/PD-L1 inhibition, considering features related to the tumor and to the host immune system.
Keywords: Biomarkers; Cancer; Immunotherapy; PD-1; PD-L1.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.
Similar articles
-
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Clin Ther. 2015. PMID: 25823918 Free PMC article. Review.
-
Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.Pharmacol Ther. 2019 Feb;194:84-106. doi: 10.1016/j.pharmthera.2018.09.008. Epub 2018 Sep 28. Pharmacol Ther. 2019. PMID: 30268773 Review.
-
Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.Drug Saf. 2019 Feb;42(2):281-294. doi: 10.1007/s40264-018-0774-8. Drug Saf. 2019. PMID: 30649742 Review.
-
Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?Clin Lung Cancer. 2016 Sep;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011. Epub 2016 Apr 6. Clin Lung Cancer. 2016. PMID: 27137346 Review.
-
Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application.Cancer Immunol Res. 2018 Oct;6(10):1122-1128. doi: 10.1158/2326-6066.CIR-18-0214. Cancer Immunol Res. 2018. PMID: 30279188
Cited by
-
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis.Explor Target Antitumor Ther. 2021;2(3):227-239. doi: 10.37349/etat.2021.00043. Epub 2021 Jun 28. Explor Target Antitumor Ther. 2021. PMID: 36046436 Free PMC article.
-
In vitro models as tools for screening treatment options of head and neck cancer.Front Med (Lausanne). 2022 Sep 7;9:971726. doi: 10.3389/fmed.2022.971726. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36160162 Free PMC article. Review.
-
A Systematic Immune and Prognostic Analysis of CD48 Interaction with Tumor Microenvironment in Pan-Cancer.Int J Gen Med. 2023 Nov 13;16:5255-5269. doi: 10.2147/IJGM.S431696. eCollection 2023. Int J Gen Med. 2023. PMID: 38021043 Free PMC article.
-
Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.Front Oncol. 2022 Sep 14;12:976224. doi: 10.3389/fonc.2022.976224. eCollection 2022. Front Oncol. 2022. PMID: 36185176 Free PMC article.
-
Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model.Mol Cancer Res. 2021 Aug;19(8):1422-1436. doi: 10.1158/1541-7786.MCR-20-0881. Epub 2021 Apr 22. Mol Cancer Res. 2021. PMID: 33888600 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
